0001683168-22-002246.txt : 20220331 0001683168-22-002246.hdr.sgml : 20220331 20220331195105 ACCESSION NUMBER: 0001683168-22-002246 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220330 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Salkind Gene CENTRAL INDEX KEY: 0001592481 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41117 FILM NUMBER: 22795137 MAIL ADDRESS: STREET 1: 1165 WRACK ROAD CITY: MEADOWBROOK STATE: PA ZIP: 19046 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mobiquity Technologies, Inc. CENTRAL INDEX KEY: 0001084267 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-ADVERTISING [7310] IRS NUMBER: 113427886 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 TORRINGTON LANE CITY: SHOREHAM STATE: NY ZIP: 11786 BUSINESS PHONE: 516-256-7766 MAIL ADDRESS: STREET 1: 35 TORRINGTON LANE CITY: SHOREHAM STATE: NY ZIP: 11786 FORMER COMPANY: FORMER CONFORMED NAME: ACE MARKETING & PROMOTIONS INC DATE OF NAME CHANGE: 19990414 4 1 ownership.xml X0306 4 2022-03-30 0 0001084267 Mobiquity Technologies, Inc. MOBQ 0001592481 Salkind Gene 35 TORRINGTON LANE SHOREHAM NY 11766 1 0 1 0 Common Stock 2022-03-30 4 C 0 1368333 1.50 A 2484354 D Notes 1.50 2022-03-30 4 C 0 2052500 D 2019-09-13 2029-09-13 Common Stock 513125 127500 D Warrants 4.00 2022-03-30 4 C 0 684166 A 2022-03-30 2029-09-30 CommonStock 684166 1237500 D The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee. Not applicable. The remaining unpaid convertible notes in the principal amount of $510,000 are convertible into 127,500 shares at $4.00 per share, excluding 63,750 warrants issuable upon conversion thereof as described in note 5. 1,237,500 derivative securities include the following: (i) 127,500 shares underlying $510,000 of debt, convertible at $4.00 per share (excluding 50% warrant coverage - i.e. 63,750 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (iii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iv) warrants to purchase 686,166 shares exercisable through September 30, 2029 which were issuable on March 30, 2022 as a result of the note conversion. /s/ Gene Salkind 2022-03-31